Live Breaking News & Updates on எடிசன் குழு|Page 16

Stay updated with breaking news from எடிசன் குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MeaTech Reports 2020 Financial Results


MeaTech Reports 2020 Financial Results
USA - English
Highlights
· Commenced trading on TASE in January 2020 and Nasdaq in March 2021: first publicly traded cultured meat company, developing sustainable and ethical food technologies.
· Finalized acquisition of Peace of Meat BV ( POM ), a pioneering Belgian developer of cultured avian meat technologies, in February 2021.
· In November 2020, successfully bio-printed an edible cultured beef fat structure grown and developed from stem cells.
· 2020 year-end cash position was $13.5 million ($8.5 million pro-forma to POM acquisition) with further $28 million raised as part of the Nasdaq listing, bringing current cash position to $33.5 million.
News provided by
Share this article
Share this article ....

Tel Aviv , Megan Paul , Ehud Helft , Alan Ryan , Sharon Fima , Prnewswire Meatech , Meatech Press Contact , Rainier Communications , Company Adss , Tel Aviv Stock Exchange , D Ltd , Edison Group , Chief Executive Officer , Nasdaq Capital Market , Tech Press Contact , Tech Investor Contacts , Meatech 3d Ltd , தொலைபேசி அவிவ் , மேகன் பால் , எஹட் உதவி , ஆலன் ரியான் , மழை தகவல்தொடர்புகள் , தொலைபேசி அவிவ் ஸ்டாக் பரிமாற்றம் , ட லிமிடெட் , எடிசன் குழு , தலைமை நிர்வாகி அதிகாரி ,

Kazia Therapeutics Ltd valuation lifts off the back of in-licensing of EVT901 drug: Edison Group


Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison Group
Much of Kazia’s operational capacity has opened up with the inclusion of paxalisib in the GBM AGILE study, and the company believes that it can dedicate significant resources to the EVT801 program.
The report also flagged a peak penetration of 15% and with the expectation of initial commercialisation in 2028.
Kazia Therapeutics Ltd’s (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company’s in-licensing of EVT801, a novel small molecule inhibitor of VEGFR3, from Evotec SE (FRA:EVT) (OTCMKTS:EVTCY) ....

Nathaniel Calloway , Edison Group , Small Caps , Harma Biotech , Kazia Therapeutics Ltd , Asx Kza , நத்யாநியல் காலோவே , எடிசன் குழு , சிறிய தொப்பிகள் ,

Kazia Therapeutics Ltd valuation lifts off the back of in-licensing of EVT901 drug: Edison Group

Kazia Therapeutics Ltd valuation lifts off the back of in-licensing of EVT901 drug: Edison Group
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Nathaniel Calloway , Edison Group , நத்யாநியல் காலோவே , எடிசன் குழு ,

OpGen Extends and Expands Partnership with New York State Department of Health to Detect Antimicrobial-Resistant Infections


Published: Apr 19, 2021
Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021
Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) OpGen, Inc.
 (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is being extended beyond the second-year expansion phase by another six months through September 30, 2021.
Having successfully achieved all of the milestones of the first and second year phases for the development of an infectious disease digital health and precision medicine platform that connects health ....

New York , United States , Matthew Bretzius , Megan Paul , Oliver Schacht , Curetis Gmb , Opgen Acuitas , Department Of Health New York , Technology Platform , Health Wadsworth Center , Edison Group , Wadsworth Center Laboratories , Wadsworth Center Deputy , York State Department Of Health , Gene Panel , Wadsworth Center , Centers For Disease , Opgen Press Contact , York State Department , Research Use Only , Opgen Inc , Exchange Commission , Opgen Acuitas Lighthouse Software , Acuitas Lighthouse Software , Securities Exchange , Acuitas Lighthouse ,